Description: MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Home Page: www.mediwound.com
42 Hayarkon Street
Yavne,
8122745
Israel
Phone:
972 7 797 14100
Officers
| Name | Title |
|---|---|
| Mr. Ofer Gonen B.Sc. | Chief Executive Officer |
| Ms. Hani Luxenburg | Chief Financial Officer |
| Mr. Yaron Meyer Adv. | Executive VP, General Counsel & Corporate Secretary |
| Dr. Ety Klinger MBA, Ph.D. | Chief Research & Development Officer |
| Dr. Lior Rosenberg M.D. | Co-Founder |
| Dr. Shmulik Hess Ph.D. | COO & Chief Commercial Officer |
| Dr. Liron Gal | Executive Director of Manufacturing Science & Technology |
| Mr. Barry J. Wolfenson | Executive Vice President of Strategy & Corporate Development |
| Dr. Robert J. Snyder CWS, D.P.M., F.A.C.F.A.S., FFPM, M.B.A., M.Sc. | Chief Medical Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.6049 |
| Price-to-Sales TTM: | 9.209 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 100 |